<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39212062</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>35</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill</ISOAbbreviation></Journal><ArticleTitle>Post-vaccination, post-infection and hybrid immunity against severe cases of COVID-19 and long COVID after infection with SARS-CoV-2 Omicron subvariants, Czechia, December 2021 to August 2023.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2300690</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2807/1560-7917.ES.2024.29.35.2300690</ELocationID><Abstract><AbstractText>BackgroundCOVID-19 remains a major infectious disease with substantial implications for individual and public health including the risk of a post-infection syndrome, long COVID. The continuous changes in dominant variants of SARS-CoV-2 necessitate a careful study of the effect of preventative strategies.AimWe aimed to estimate the effectiveness of post-vaccination, post-infection and hybrid immunity against severe cases requiring oxygen support caused by infections with SARS-CoV-2 variants BA1/2 and BA4/5+, and against long COVID in the infected population and their changes over time.MethodsWe used a Cox regression analysis with time-varying covariates and calendar time and logistic regression applied to national-level data from Czechia from December 2021 until August 2023.ResultsRecently boosted vaccination, post-infection and hybrid immunity provide significant protection against a severe course of COVID-19, while unboosted vaccination more than 10 months ago has a negligible protective effect. The post-vaccination immunity against the BA1/2 or BA4/5+&#x2009;variants, especially based on the original vaccine types, appears to wane rapidly compared with post-infection and hybrid immunity. Once infected, however, previous immunity plays only a small protective role against long COVID.ConclusionVaccination remains an effective preventative measure against a severe course of COVID-19 but its effectiveness wanes over time thus highlighting the importance of booster doses. Once infected, vaccines may have a small protective effect against the development of long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#x160;m&#xed;d</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Modelling of Biological and Social Processes, Prague, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Econometrics, Institute of Information Theory and Automation, Czech Academy of Sciences, Prague, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barusov&#xe1;</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biostatistics and Analyses, Ltd., Brno, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarkovsk&#xfd;</LastName><ForeName>Ji&#x159;&#xed;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xe1;jek</LastName><ForeName>Ond&#x159;ej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavl&#xed;k</LastName><ForeName>Tom&#xe1;&#x161;</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#x159;ibylov&#xe1;</LastName><ForeName>Lenka</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, Faculty of Science, Masaryk University, Brno, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinerov&#xe1;</LastName><ForeName>Josef&#xed;na</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychology, University of Nottingham, University Park, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaj&#xed;&#x10d;ek</LastName><ForeName>Milan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Modelling of Biological and Social Processes, Prague, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Econometrics, Institute of Information Theory and Automation, Czech Academy of Sciences, Prague, Czechia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trnka</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Modelling of Biological and Social Processes, Prague, Czechia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>All authors contributed equally to this work.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czechia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018153" MajorTopicYN="N" Type="Geographic">Czech Republic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BA1/2</Keyword><Keyword MajorTopicYN="N">BA4/5</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">hybrid immunity</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword><Keyword MajorTopicYN="N">waning</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>30</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39212062</ArticleId><ArticleId IdType="pmc">PMC11484334</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.35.2300690</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriover MD, Do&#x11f;anay HL, Akova M, G&#xfc;ner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-22. 10.1016/S0140-6736(21)01429-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01429-X</ArticleId><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35-45. 10.1001/jama.2021.8565</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.8565</ArticleId><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira ED, Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386(20):1910-21. 10.1056/NEJMoa2200674</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200674</ArticleId><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;m&#xed;d M, Berec L, P&#x159;ibylov&#xe1; L, M&#xe1;jek O, Pavl&#xed;k T, Jarkovsk&#xfd; J, et al. Protection by vaccines and previous infection against the omicron variant of severe acute respiratory syndrome coronavirus 2. J Infect Dis. 2022;226(8):1385-90. 10.1093/infdis/jiac161</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac161</ArticleId><ArticleId IdType="pmc">PMC9129207</ArticleId><ArticleId IdType="pubmed">35482442</ArticleId></ArticleIdList></Reference><Reference><Citation>Berec L, &#x160;m&#xed;d M, P&#x159;ibylov&#xe1; L, M&#xe1;jek O, Pavl&#xed;k T, Jarkovsk&#xfd; J, et al. Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. PLoS One. 2022;17(7):e0270801. 10.1371/journal.pone.0270801</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0270801</ArticleId><ArticleId IdType="pmc">PMC9269461</ArticleId><ArticleId IdType="pubmed">35802590</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 2023;11(12):1089-100. 10.1016/S2213-2600(23)00306-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00306-5</ArticleId><ArticleId IdType="pubmed">37898148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura N, Otani K, Kinoshita R, Yan F, Takizawa Y, Fukushima K, et al. Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan. Lancet Reg Health West Pac. 2023;41:100911. 10.1016/j.lanwpc.2023.100911</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100911</ArticleId><ArticleId IdType="pmc">PMC10786644</ArticleId><ArticleId IdType="pubmed">38223396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerson BK, Bruxvoort KJ, Qian L, Sy LS, Qiu S, Tubert JE, et al. Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages. Hum Vaccin Immunother. 2024;20(1):2335052. 10.1080/21645515.2024.2335052</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2024.2335052</ArticleId><ArticleId IdType="pmc">PMC10996830</ArticleId><ArticleId IdType="pubmed">38575149</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11(1):22777. 10.1038/s41598-021-02321-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02321-z</ArticleId><ArticleId IdType="pmc">PMC8611039</ArticleId><ArticleId IdType="pubmed">34815503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023;11(5):439-52. 10.1016/S2213-2600(23)00015-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00015-2</ArticleId><ArticleId IdType="pmc">PMC9917454</ArticleId><ArticleId IdType="pubmed">36780914</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang ZR, Jiang YW, Li FX, Liu D, Lin TF, Zhao ZY, et al. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4(4):e236-46. 10.1016/S2666-5247(22)00390-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(22)00390-1</ArticleId><ArticleId IdType="pmc">PMC9974155</ArticleId><ArticleId IdType="pubmed">36868258</ArticleId></ArticleIdList></Reference><Reference><Citation>Laake I, Skodvin SN, Blix K, Caspersen IH, Gjessing HK, Juvet LK, et al. Effectiveness of mRNA booster vaccination against mild, moderate, and severe covid-19 caused by the omicron variant in a large, population-based, Norwegian cohort. J Infect Dis. 2022;226(11):1924-33. 10.1093/infdis/jiac419</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac419</ArticleId><ArticleId IdType="pmc">PMC9620770</ArticleId><ArticleId IdType="pubmed">36259543</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Gidding H, Stepien S, Cretikos M, Macartney K. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection. Vaccine. 2022;40(43):6288-94. 10.1016/j.vaccine.2022.09.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.09.029</ArticleId><ArticleId IdType="pmc">PMC9489983</ArticleId><ArticleId IdType="pubmed">36180375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai FTT, Yan VKC, Wan EYF, Chan CIY, Wei C, Cheng FWT, et al. COVID-19 vaccine effectiveness against the Omicron variant of SARS-CoV-2 in multimorbidity: A territory-wide case-control study. iScience. 2024;27(4):109428. 10.1016/j.isci.2024.109428</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.109428</ArticleId><ArticleId IdType="pmc">PMC10966310</ArticleId><ArticleId IdType="pubmed">38544567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett JC, Luiten KG, O&#x2019;Hanlon J, Han PD, McDonald D, Wright T, et al. Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection. Vaccine. 2024;42(6):1332-41. 10.1016/j.vaccine.2024.01.080</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.01.080</ArticleId><ArticleId IdType="pubmed">38307746</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MO, Kamigaki T, Thandar MM, Haruyama R, Yan F, Shibamura-Fujiogi M, et al. Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis. BMJ Open. 2023;13(12):e076892. 10.1136/bmjopen-2023-076892</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-076892</ArticleId><ArticleId IdType="pmc">PMC10748972</ArticleId><ArticleId IdType="pubmed">38128943</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph AE, Khan FL, Shah A, Singh TG, Wiemken TL, Puzniak LA, et al. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against symptomatic covid-19 among immunocompetent individuals testing at a large us retail pharmacy. J Infect Dis. 2024;229(3):648-59. 10.1093/infdis/jiad474</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad474</ArticleId><ArticleId IdType="pmc">PMC10938215</ArticleId><ArticleId IdType="pubmed">37925630</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385. 10.1136/bmjmed-2022-000385</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000385</ArticleId><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Ibarguengoitia ME, Rodr&#xed;guez-Torres JF, Garza-Silva A, Rivera-Cavazos A, Morales-Rodriguez DP, Hurtado-Cabrera M, et al. Association of vaccine status, reinfections, and risk factors with Long COVID syndrome. Sci Rep. 2024;14(1):2817. 10.1038/s41598-024-52925-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-52925-4</ArticleId><ArticleId IdType="pmc">PMC10837423</ArticleId><ArticleId IdType="pubmed">38307886</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Mercad&#xe9;-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med. 2024;12(3):225-36. 10.1016/S2213-2600(23)00414-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh NT, J&#xf6;dicke AM, Catal&#xe0; M, Mercad&#xe9;-Besora N, Hayati S, Lupattelli A, et al. Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway. Lancet Respir Med. 2024;12(5):e33-4. 10.1016/S2213-2600(24)00082-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(24)00082-1</ArticleId><ArticleId IdType="pubmed">38614106</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousaf AR, Mak J, Gwynn L, Bloodworth R, Rai R, Jeddy Z, et al. 1935. COVID-19 mRNA vaccination reduces the occurrence of post-COVID conditions in U.S. children aged 5-17 years following omicron SARS-CoV-2 infection, July 2021-september 2022. Open Forum Infect Dis. 2023;10(Suppl 2) Supplement_2;ofad500.2466. 10.1093/ofid/ofad500.2466</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad500.2466</ArticleId><ArticleId IdType="pmc">PMC10878356</ArticleId><ArticleId IdType="pubmed">38379567</ArticleId></ArticleIdList></Reference><Reference><Citation>Razzaghi H, Forrest CB, Hirabayashi K, Wu Q, Allen AJ, Rao S, et al. Vaccine effectiveness against long covid in children. Pediatrics. 2024;153(4):e2023064446. 10.1542/peds.2023-064446</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2023-064446</ArticleId><ArticleId IdType="pmc">PMC10979300</ArticleId><ArticleId IdType="pubmed">38225804</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10 Version:2019). Geneva: WHO; 2019. Available from: https://icd.who.int/browse10/2019/en</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variants of concern. Stockholm: ECDC. [Accessed: 20 Feb 2022]. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern</Citation></Reference><Reference><Citation>Sk&#xe1;la K. (Post-COVID syndrome/disability: definition, diagnosis and classification). Neumannov&#xe1;, Kobl&#xed;&#x17e;ek &#x10c;PF &#x10c;LS JEP working group. Post-covid syndrom/posti&#x17e;en&#xed;: definice, diagnostika a klasifikace. Stud Pneumol Phtiseol. 2021;81(5):215.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529. 10.1136/bmj-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, et al. Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. JAMA Intern Med. 2023;183(6):566-80. 10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461-7. 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>